VanEck Pharmaceutical ETF PPH
121.59 USD +0.34 (+0.28%)
At closeNov 10, 2026, 4:00 PM EST
121.59 0.00 -0.00%
After hours · Nov 10, 4:00 PM ET
120.21 Day range 121.75
95.90 52-week range 123.53
- YTD
- +17.86%
- 1 year
- +27.24%
News
fool.com Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF VanEck Pharmaceutical ETF provides a higher dividend yield and lower price volatility compared to the State Street fund. State Street SPDR Pharmaceuticals ETF offers a more diversified portfolio with…
seekingalpha.com PPH: Key Pharmaceutical Innovations Support Bullish Outlook (Upgrade) VanEck Pharmaceutical ETF is upgraded to Buy, driven by innovation in weight-loss treatments and robust product pipelines among top holdings. PPH's concentrated exposure to Eli Lilly, Merck, and Novo…
fool.com Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
fool.com Which Healthcare ETF Is the Better Buy: Simplify's Active PINK or VanEck's Pharma-Focused PPH? Simplify Health Care ETF has a higher expense ratio and a lower dividend yield than VanEck Pharmaceutical ETF. VanEck Pharmaceutical ETF maintains a more concentrated portfolio focused exclusively on…
zacks.com Execution of Pharma Tariffs Brings These ETFs Into Focus Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
zacks.com Should You Invest in the VanEck Pharmaceutical ETF (PPH)? Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on…
fool.com Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP The VanEck Pharmaceutical ETF offers a lower expense ratio of 0.36% compared to 0.58% for the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has delivered a higher 1-year total return…
fool.com VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
fool.com Should You Bet Big on Drugmakers? VanEck Pharmaceutical ETF vs. The Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to 26 for the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF currently offers a…
zacks.com Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
zacks.com FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
fool.com Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
fool.com Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? VanEck Pharmaceutical ETF offers a lower-volatility profile and a higher 1.9% dividend yield compared to State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF provides broad exposure…
fool.com PPH vs. IYH: Which Healthcare Fund Is the Better Buy? PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
fool.com VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.
zacks.com Should You Invest in the VanEck Pharmaceutical ETF (PPH)? Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity…
fool.com Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio? The State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio and higher assets under management than the VanEck Pharmaceutical ETF VanEck Pharmaceutical ETF focuses…
benzinga.com Two Years to Build or Pay 200% — Which US Pharma Stocks Win? Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
fool.com Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ The iShares Global Healthcare ETF provides broader exposure with 110 holdings across various sub-sectors compared to the 26 positions in the VanEck Pharmaceutical ETF The VanEck Pharmaceutical ETF…
fool.com For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
seekingalpha.com AI Bubble Risks Make Dividend Stocks Attractive Again I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates…
benzinga.com Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery Bristol Myers Squibb expands AI efforts through Anthropic and Tempus partnerships as shares edge higher Wednesday.
benzinga.com What's Going On With Merck Stock Tuesday? Merck begins tender offer for Terns at $53 per share as part of its planned acquisition announced in March 2026.
benzinga.com Biotech ETF With A Twist: Defiance To Donate Initial Advisory Profits To Autism Causes Ahead of April, also the autism acceptance month, Defiance filed for a biopharma ETF with a pledge to donate profits to autism services and research.
benzinga.com Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery Merck teams up with Mayo Clinic to use AI for drug discovery, focusing on inflammatory diseases and more.
benzinga.com Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
benzinga.com Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus Novo Nordisk's FDA-approved weight-loss pill intensifies its rivalry with Eli Lilly, putting health care and biotech ETFs in focus.
benzinga.com Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
benzinga.com Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.
benzinga.com Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
benzinga.com Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
benzinga.com Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
benzinga.com Trump's Weight-Loss Drug Push May Put These ETFs On A Diet Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.
benzinga.com Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
benzinga.com Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
benzinga.com Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
benzinga.com Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
benzinga.com Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
benzinga.com Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
benzinga.com Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
benzinga.com Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
benzinga.com Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
benzinga.com Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its…
benzinga.com Getting Into The Drug Business: From NDAs To PDUFA Dates 
benzinga.com New Study Suggests Drug Prices Have Doubled Since 2011: What's It Mean For The Market? 
benzinga.com ETFs For The Next Pharma Takeover Candidates 
benzinga.com Pharmaceutical ETFs Are Health Care Sector Standouts 
benzinga.com 3 Ways To Profit From Merger Activity In The Pharmaceutical Sector 
benzinga.com Earnings Trigger Volume Spike in Pharma ETF - benzinga.com ETF Showdown: A Pharma Fight